Log in

NYSE:ABBV - AbbVie Stock Price, Forecast & News

$94.05
-1.30 (-1.36 %)
(As of 02/16/2020 04:00 PM ET)
Today's Range
$93.77
Now: $94.05
$95.30
50-Day Range
$81.02
MA: $87.98
$97.79
52-Week Range
$62.66
Now: $94.05
$97.86
Volume11.17 million shs
Average Volume10.48 million shs
Market Capitalization$139.08 billion
P/E Ratio17.81
Dividend Yield4.95%
Beta0.96
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorN/A
CUSIP00287Y10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$9.21 per share
Book Value($5.61) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Employees30,000
Outstanding Shares1,478,820,000
Market Cap$139.08 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a -- dividend on Friday, November 1st. Investors of record on Wednesday, January 15th will be paid a dividend of $1.18 per share on Friday, February 14th. This represents a dividend yield of 5.93%. The ex-dividend date is Tuesday, January 14th. This is an increase from AbbVie's previous -- dividend of $1.07. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has authorized a share buyback plan on Thursday, December 13th 2018, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's leadership believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, February, 7th. The company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.19 by $0.02. The company earned $8.70 billion during the quarter, compared to the consensus estimate of $8.68 billion. AbbVie had a net margin of 23.69% and a negative return on equity of 162.37%. AbbVie's revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.90 EPS. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY20 earnings guidance on Friday, February, 7th. The company provided EPS guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus estimate of $9.78.

What price target have analysts set for ABBV?

14 analysts have issued 12-month price objectives for AbbVie's stock. Their forecasts range from $66.61 to $104.00. On average, they expect AbbVie's share price to reach $88.72 in the next year. This suggests that the stock has a possible downside of 5.7%. View Analyst Price Targets for AbbVie.

What is the consensus analysts' recommendation for AbbVie?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AbbVie.

Has AbbVie been receiving favorable news coverage?

News coverage about ABBV stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AbbVie earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for AbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.65%), FMR LLC (2.72%), Bank of New York Mellon Corp (1.02%), Renaissance Technologies LLC (0.80%), Charles Schwab Investment Management Inc. (0.47%) and Sumitomo Mitsui Trust Holdings Inc. (0.40%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Skandinaviska Enskilda Banken AB publ , Victory Capital Management Inc., Levin Easterly Partners LLC, Bank of New York Mellon Corp, Bank of Montreal Can, Pinebridge Investments L.P. and Oakbrook Investments LLC. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.

Which major investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Farallon Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Amundi Pioneer Asset Management Inc., MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd and Lord Abbett & CO. LLC. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $94.05.

How big of a company is AbbVie?

AbbVie has a market capitalization of $139.08 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,100 (Vote Outperform)
Underperform Votes:  779 (Vote Underperform)
Total Votes:  1,879
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Balance Sheet

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel